Nabriva Therapeutics AG

Nabriva Therapeutics — Investor Presentation (April 2021)

30 slides from Nabriva Therapeutics's investor presentation, Apr 15, 2021

  1. Slide 1: Uniquely Positioned to Deliver Innovative Treatments for Patients with Infectious Diseases

    UNIQUELY POSITIONED TO DELIVER INNOVATIVE TREATMENTS FOR PATIENTS WITH INFECTIOUS DISEASES April 2021

  2. Slide 2: Safe Harbor and Disclaimer

    Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about its ability to successfully commercialize XENLETA for the treatment of CABP, including the availability of and ease of

  3. Slide 3: Nabriva Recent Corporate Highlights

    Nabriva Recent Corporate Highlights Positive Momentum and Important Milestones in Light of COVID-19 Challenges 3 ✓ Strengthened Balance Sheet ✓ Prudent financial management ✓ Continued assessment of pipeline/ lifecycle management and business development opportunities ✓ Regulatory approvals in Europ

  4. Slide 4: Looking to the Future: 2021 Key Objectives

    Looking to the Future 2021 Key Objectives * CONTEPO is an investigational drug candidate and has not received regulatory approval for any indication. Information provided in this slide is based on research and development performed to date. Resubmit Contepo™ NDA after FDA clarifies international pla

  5. Slide 5: Nabriva Leadership Team

    Nabriva Leadership Team Significant Commercial and Development Experience in Serious and Rare Diseases 5

  6. Slide 6: XENLETA and SIVEXTRO Commercial Opportunity

    XENLETA and SIVEXTRO COMMERCIAL OPPORTUNITY

  7. Slide 7: XENLETA: A Promising Treatment Option for CABP

    Complete Spectrum of Coverage of Main CABP Pathogens Monotherapy with appropriate spectrum for CABP aligned with principles of antimicrobial stewardship; Low risk of C. difficile infection Generally Well Tolerated Low rates of discontinuations due to adverse events in Phase 3 clinical trials New Cla

  8. Slide 8: Pneumonia: A Leading Cause of Morbidity, Mortality and Healthcare Cost

    Pneumonia: A Leading Cause of Morbidity, Mortality and Healthcare Cost Macrolide resistance in respiratory isolates ≥25% in all regions of the U.S. #3 Cause of hospital readmission6 ~5MM Cases Annually in US1 #5 Cause of total hospitalizations7 #1 Cause of infectious death5 Mortality rate ~$17B ~15%

  9. Slide 9: Recognized Fluoroquinolone Safety Concerns

    Recognized Fluoroquinolone Safety Concerns FDA web site: Fluoroquinolone antimicrobial drugs information. EMA website: https://www.ema.europa.eu/en/news/fluoroquinolone-quinolone-antibiotics-prac-recommends-new-restrictions-use-following-review Communications Issued by FDA and EMA 2008 2011 2013 201

  10. Slide 10: SIVEXTRO: Once Daily, Short Course Monotherapy for ABSSSI

    SIVEXTRO: Once Daily, Short Course Monotherapy for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 10 For ABSSSI Adults and Adolescent Patients • Potent activity against a broad range of pathogens, including MRSA • Adverse reactions leading to discontinuation: 1.0% in clinical trials •On

  11. Slide 11: SIVEXTRO: Nabriva Began Direct Distribution on April 12th

    SIVEXTRO: Nabriva began direct distribution on April 12th Recording 100% of Net Sales Under Product Sales 11 Q4 2020 60 Reps Deployed • Prior to April 12th, all gross sales fell under Merck NDC • A portion of gross sales recorded as collaboration revenue by Nabriva Nabriva anticipates seeing the ret

  12. Slide 12: XENLETA & SIVEXTRO: Synergies in the Community

    XENLETA & SIVEXTRO: Synergies in the Community Primary Care Podiatrists & Dermatologists Urgent Care A: Symphony Health a PRA Health Sciences company, estimated treatment courses, TRXs for 12 months ending June 2017 B: IQVIA: Community Market data analysis, 2018; Medical Claims (Dx) and Longitudinal

  13. Slide 13: Sales Force Deployment

    Sales Force Deployment 60 Territory Footprint Expected to Efficiently Engage 7,800 Target Customers 13 Sales Force Profile: • ~10 years community sales experience • Prior antibiotic sales and Specialty Pharmacy pull- through expertise • Extensive experience selling in-person and optimizing virtual e

  14. Slide 14: Significant Number of Nabriva Interactions with Targets

    Significant Number of Nabriva Interactions with Targets 37,000 Total Sales Calls Since October 2020 Represents ~96% of potential top two decile SIVEXTRO prescribers and 98% of potential top decile XENLETA prescribers 14 0 2000 4000 6000 8000 10000 12000 Family Medicine Podiatry Dermatology Infectiou

  15. Slide 15: Managed Care - XENLETA: Major Wins to Date

    Managed Care - XENLETA: Major Wins to Date >248MM with XENLETA on Formulary and Further Expanding Coverage in 2021 15 92% of Total Commercial Lives have access to XENLETA >78% Unrestricted Payer/PBM Status Express Scripts PBM Unrestricted United Health Group Unrestricted Anthem, Inc. Covered (PA/ST)

  16. Slide 16: Managed Care - SIVEXTRO: Major Wins to Date

    Managed Care - SIVEXTRO: Major Wins to Date >269MM with SIVEXTRO® on Formulary 93% of Total Commercial Lives have access to SIVEXTRO® Covered (PA/ST) Unrestricted Source: MMIT Data 3/26/2021 ~60% Unrestricted Payer/PBM Status United Health Group Unrestricted CVS Unrestricted Department of Defense –

  17. Slide 17: Further Exploration of XENLETA (lefamulin) for Cystic Fibrosis

    Further Exploration of XENLETA (lefamulin) for Cystic Fibrosis

  18. Slide 18: Unmet Need in Cystic Fibrosis Patients with Persistent MRSA Infections

    Unmet Need in Cystic Fibrosis Patients with Persistent MRSA Infections MRSA Associated with Poorer Outcomes 18 No approved treatments for acute exacerbations or chronic treatment of S. aureus 1. Annual Data Report 2018 Cystic Fibrosis Foundation Patient Registry 2. Annual Data Report 2019 Cystic Fib

  19. Slide 19: Oral Outpatient Utilization Rates for CF Patients with Chronic MRSA

    Oral Outpatient Utilization Rates for CF Patients with Chronic MRSA during an Acute Pulmonary Exacerbation 19 Survey of 152 CF Centers on Outpatient Antibiotic Utilization for MRSA1 No MRSA Rx consensus 1. Zobell,JT, et al. Pediatr Pulmonol. 2015;50(6):552-9. 2. Suwantarat N, et al. Diag Micro and I

  20. Slide 20: Potential for XENLETA to Treat CF Patients with S. Aureus

    Potential for XENLETA to Treat CF Patients with S. Aureus Efficacy in CABP Oral and IV formulations Potent activity against S. aureus Activity in biofilms Low mutation frequency Lung penetration –ELF; Macrophage Anti-inflammatory activity Safety profile (no renal toxicity) Potential Peak Sales of $1

  21. Slide 21: CONTEPO Commercial Opportunity

    CONTEPO COMMERCIAL OPPORTUNITY

  22. Slide 22: CONTEPO: A Potential Alternative to Pip/Taz and Carbapenems

    In-Patients Prioritized Accounts CONTEPO: A Potential Alternative to Pip/Taz and Carbapenems Attractive Carbapenem-sparing Monotherapy for cUTI Patients at Risk for MDR Organisms (2) ▪ Large unmet need in the United States in treating patients with MDR gram-negative infections, with mortality increa

  23. Slide 23: Approved for a Broad Range of Serious Infections

    Approved for a broad range of serious infections including***: – Postoperative infections, concomitant nephrolithiasis, Hydronephrosis, tumours and prostatitis – orthopaedics and traumatology: postoperative bone infections (infected Osteosynthesis, endoprosthesis), osteomyelitis, purulent arthritis,

  24. Slide 24: CONTEPO: Current Regulatory Status

    • Type A meeting held with the FDA on October 30th to obtain information related to the Agency’s thinking on the conduct of foreign inspections • The FDA informed us that it has not yet determined how it will conduct international inspections during the COVID-19 pandemic • Next steps and specific ti

  25. Slide 25: Focusing on Nabriva's Future

    FOCUSING ON NABRIVA’S FUTURE

  26. Slide 26: Financial Highlights

    26 Q4 2020 Q3 2020 Financial Highlights Q1 2021 Q2 2021 Q2 2021 •Cash & short-term investments = $41.6MM as of December 31st •Net proceeds of $35MM from recent financing and proceeds from ATM extends cash runway into Q4 21 •Record 100% of SIVEXTRO net sales starting on April 12th •Continued prudent

  27. Slide 27: Nabriva's Pipeline and Commercialized Products

    Nabriva’s Pipeline and Commercialized Products *Nabriva Therapeutics in commercial partnership with Sunovion for Canada. Program Indications Discovery Pre- clinical Phase 1 Phase 2 Phase 3 NDA/ MAA Filing Approval Comments XENLETA lefamulin (IV/oral) CABP FDA approval – August 2019 EMA approval – Ju

  28. Slide 28: 2021 Key Objectives

    2021 Key Objectives Remain Nimble and Optimize Resources in Light of Ever Changing COVID Environment * CONTEPO is an investigational drug candidate and has not received regulatory approval for any indication. Information provided in this slide is based on research and development performed to date.

  29. Slide 29: Appendix

    Appendix 29

  30. Slide 30: References for Slide

    References for Slide 8 MIC=minimum inhibitory concentration. *Data presented are from 2010 to September 2019. Dataset provided by JMI Labs and the SENTRY Antimicrobial Surveillance Program. sentry-mvp.jmilabs.com. Accessed October 5, 2019. 1. National Ambulatory Medical Care Survey (NAMCS) and Natio

Nabriva Therapeutics — Investor Presentation (April 2021) on 6ix